WO2020226467A1 - Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation - Google Patents

Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation Download PDF

Info

Publication number
WO2020226467A1
WO2020226467A1 PCT/KR2020/006170 KR2020006170W WO2020226467A1 WO 2020226467 A1 WO2020226467 A1 WO 2020226467A1 KR 2020006170 W KR2020006170 W KR 2020006170W WO 2020226467 A1 WO2020226467 A1 WO 2020226467A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
strain
bowel disease
inflammatory bowel
enterococcus lactis
Prior art date
Application number
PCT/KR2020/006170
Other languages
English (en)
Korean (ko)
Inventor
채성욱
지건영
홍성욱
노성운
이호재
Original Assignee
한국 한의학 연구원
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원, 한국식품연구원 filed Critical 한국 한의학 연구원
Publication of WO2020226467A1 publication Critical patent/WO2020226467A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Definitions

  • the present invention relates to a strain of Enterococcus lactis WiKim0107 having an effect of regulating immune function and improving inflammatory bowel disease and its use.
  • Skate belonging to the stingray family, is a cartilage, benthic fish, and is distributed in the coast of Heuksan Island and the west coast of Korea, and is caught in Mokpo and Yeongwang, but due to the recent decline, it is also imported from Chile, convinced, and Argentina.
  • Jeollanam-do fermented skates are used habitually as a traditional food, and the population who enjoys its unique aroma and taste is increasing.
  • Hongtak which is eaten with fermented skateboard with makgeolli, is the most famous, and in the southeastern coast of Jeollanam-do, fermented skateboard is hardly missed for feast food.
  • Skatefish contains a lot of nitrogen compounds, urea and trimethylamine oxide, in the body to control the osmotic pressure in the deep sea, and these components are converted into ammonia and trimethylamine by fermentation, which irritates the nose. A stinging taste is produced.
  • Skate is a high-protein, low-fat fish with 19% protein and 0.9% fat. Like sharks and rays, it contains a lot of betaine and taurine, and has a high content of calcium and urea.
  • the reported functional effects of skate include cell membrane stabilization, cholesterol-regulating effects to prevent vascular disease and heart failure, taurine, which is important for growth and development, linolenic acid and arachidonic acid, which help reduce serum cholesterol and improve brain growth and cognitive function.
  • IBD inflammatory bowel disease
  • Crohn's disease or Behcet's disease a disease including ulcerative colitis, Crohn's disease or Behcet's disease, and it is known that the activation of inflammatory cells is an important etiology, and the activation of inflammatory cells with anti-inflammatory agents, immunosuppressants, etc. Treatment through inhibition is necessary. That is, even in the case of bowel disease, the treatment method must be different depending on the specific etiology, and in particular, in the case of inflammatory bowel disease, the provision of a method for suppressing and alleviating inflammation-related symptoms is the most important factor in the treatment of the disease.
  • Persistent or inadequate activation of the intestinal immune system plays an important role in the pathophysiology of chronic mucosal inflammation, especially infiltrating neutrophils, macrophages, lymphocytes and mast cells, resulting in mucosal destruction and ulcers.
  • TNF- ⁇ is highly expressed in the colon lumen and colon epithelial cells of patients with ulcerative colitis, and according to recent studies, TNF- ⁇ is known to play an important role in the pathogenesis of ulcerative colitis.
  • Infliximab an anti-TNF- ⁇ antibody, is known to be effective not only for the treatment of boils, but also for the treatment of previously untreated Crohn's disease, but these treatments are expensive, and some patients suffer from fluid reactions or infectious complications. The same side effects are caused.
  • 5-aminosalicylic acid drugs that block the production of prostaglandins, such as sulfasalazine, are used, or immunosuppressants such as steroids are used.
  • Sulfasalazine is likely to cause side effects or adverse effects such as fullness, headache, rash, liver disease, leukopenia, agranulocytosis, and male infertility.
  • Steroid-type immunosuppressants are adrenal cortical steroids, which are recognized for their short-term effects, but cannot improve long-term prognosis, and induced infectious diseases, secondary adrenal insufficiency, peptic ulcer, diabetes, mental disorders, steroidal nephropathy, etc.
  • induced infectious diseases secondary adrenal insufficiency, peptic ulcer, diabetes, mental disorders, steroidal nephropathy, etc.
  • Korean Patent Publication No. 2019-0005125 discloses an anti-influenza virus composition containing Enterococcus canintestini strain
  • Korean Patent No. 1909936 discloses an anti-influenza virus composition containing fermented lactic acid bacteria of natural food ingredients.
  • a functional food composition for enhancing immune activity and a method for producing the same have been disclosed, there has not been disclosed a strain of Enterococcus lactis WiKim0107 having an effect of regulating immune function and improving inflammatory bowel disease of the present invention and its use.
  • the present invention is derived from the above requirements, the present invention provides an Enterococcus lactis WiKim0107 strain having an effect of modulating immune function and improving inflammatory bowel disease, and the Enterococcus lactis WiKim0107 strain is cytotoxic There is no immunity, it has the effect of promoting NO production and ROS production, enhancing the expression of inflammatory cytokines and the number of immune cells, and confirming that there is an effect of improving bowel disease in an animal model of inflammatory bowel disease. The invention was completed.
  • the present invention provides an Enterococcus lactis WiKim0107 strain (Accession No.: KACC 81090BP) having an effect of regulating immune function and preventing, improving or treating inflammatory bowel disease.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It provides a health functional food composition for controlling and preventing or improving inflammatory bowel disease.
  • the present invention is an inflammatory bowel comprising as an active ingredient at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture. It provides a pharmaceutical composition for preventing or treating diseases.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It provides a feed composition for controlling and preventing or improving inflammatory bowel disease.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It provides a veterinary composition for controlling and preventing or treating inflammatory bowel disease.
  • the present invention relates to lactic acid bacteria Enterococcus lactis having an effect of regulating immune function and improving inflammatory bowel disease and its use, and Enterococcus lactis WiKim0107 of the present invention has no cytotoxicity, has an immune enhancing effect, and NO It has the effect of promoting production and ROS production, increasing the expression of inflammatory cytokines and the number of immune cells, and has the effect of improving bowel disease in an animal model of inflammatory bowel disease, so it is used for controlling immune function and preventing, improving or treating inflammatory bowel disease. It can be very useful in health functional food, pharmaceutical, feed composition or veterinary composition.
  • Con is a cell that has not been treated with anything
  • PBS is a cell treated with PBS solution to confirm that there is no difference due to solvent
  • LPS is a cell treated with lipopolysaccharide
  • WiKim0107 is 10 4 ⁇ 10 7 CFU/ It was treated with ml of Enterococcus lactis. * Indicates that there is a statistically significant difference compared to Con, which is p ⁇ 0.05.
  • FIG. 4 is an analysis result of NO (Nitric oxide) production (A), iNOS expression (B) and ROS (Reactive oxygen species) production (C) according to Enterococcus lactis (WiKim0107) treatment of the present invention.
  • NO Nitric oxide
  • B iNOS expression
  • C Reactive oxygen species
  • Figure 5 is interleukin (IL)-1 ⁇ (A), IL-6 (B), tumor necrosis factor alpha (TNF- ⁇ ) (C) and cyclooxygenase 2 (in accordance with the treatment of Enterococcus lactis (WiKim0107) of the present invention) It is the result of gene expression analysis of COX-2)(D). * LPS treatment compared to Con; And the group treated with Enterococcus lactis (WiKim0107) of the present invention; p ⁇ 0.05, indicating that the gene expression was increased.
  • FIG. 6 is a result of confirming the weight change (A), the distribution of immune cells (B), and the gene expression level of inflammatory cytokines (C) by administering Enterococcus lactis (WiKim0107) of the present invention to an animal model. * Indicates that the gene expression was increased in the group treated with Enterococcus lactis (WiKim0107) of the present invention compared to Con, p ⁇ 0.05.
  • A body weight
  • DAI intestinal disease activity index
  • WiKim0107 length change of colon tissue after administration of Enterococcus lactis
  • T cells T cells, B cells, NK cells, macrophages, dendritic cells
  • Enterococcus lactis WiKim0107
  • the present invention relates to an Enterococcus lactis WiKim0107 strain (Accession No.: KACC 81090BP) having an effect of regulating immune function and preventing, improving or treating inflammatory bowel disease.
  • the Enterococcus lactis WiKim0107 strain is preferably isolated from skateboard or skate kimchi, but is not limited thereto.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It relates to a health functional food composition for controlling and preventing or improving inflammatory bowel disease.
  • the active ingredient is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
  • the strain or a culture solution thereof may be added as it is, or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. have.
  • the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the health functional food composition of the present invention may further include ingredients that are commonly added at the time of food production and are food wise acceptable.
  • ingredients that are commonly added at the time of food production and are food wise acceptable For example, when prepared as a beverage, it may further include one or more components from citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, etc. in addition to the strain of the present invention.
  • the amount that can be included as an active ingredient of the health functional food composition according to the present invention is appropriately selected according to the age, sex, weight, condition, and symptoms of a person who wants a health functional food for controlling immune function and preventing or improving inflammatory bowel disease. It may be, and preferably contained in about 0.01 to 10.0g per adult basis, and by ingesting foods having such a content, it is possible to obtain an effect of controlling immune function and preventing or improving inflammatory bowel disease.
  • the present invention is an inflammatory bowel comprising as an active ingredient at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture. It relates to a pharmaceutical composition for preventing or treating diseases.
  • the inflammatory bowel disease is preferably ulcerative colitis, Crohn's disease, or Behcet's disease, but is not limited thereto.
  • the term'prevention' in the present invention refers to any action that suppresses or delays the onset of inflammatory bowel disease by administration of the pharmaceutical composition according to the present invention, and'treatment' refers to inflammatory bowel by administration of the pharmaceutical composition. It refers to any action in which the symptoms of the suspected and onset individual are improved or beneficially altered.
  • the pharmaceutical composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
  • compositions according to the present invention are formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to a conventional method. Can be used.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium And various compounds or mixtures including silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, in the strain or the endoplasmic reticulum derived from the strain. , Sucrose (sucrose) or lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
  • As a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term'pharmaceutically effective amount' of the present invention is sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical prevention or treatment. It means an amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion, treatment The duration, factors including drugs used in combination or co-use with the composition of the present invention used, and other factors well known in the medical field.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered single or multiple. Considering all of the above factors, it is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects.
  • the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or divided into several doses.
  • the above dosage does not in any way limit the scope of the present invention.
  • the term "individual" of the present invention includes, without limitation, mammals including mice, livestock, humans, etc. that are likely to develop inflammatory bowel disease or have developed.
  • the route of administration of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue.
  • the pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered through a route such as oral administration or rectal administration, and in some cases, may be administered by other routes depending on the purpose.
  • the oral composition should be coated with an active agent or formulated to protect it from degradation in the stomach.
  • the composition can be administered by any device capable of moving the active substance to the target cell.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It relates to a feed composition for controlling and preventing or improving inflammatory bowel disease.
  • the strain is as described above, and may be added as a feed composition for the purpose of regulating immune function and preventing or improving inflammatory bowel disease.
  • the feed composition may contain a feed additive.
  • the feed additive of the present invention corresponds to an auxiliary feed in the feed management law.
  • the term'feed' may mean any natural or artificial diet, one meal meal, etc., or a component of the one meal meal for animals to eat, ingest, and digest.
  • the kind of feed is not particularly limited, and feed commonly used in the art may be used.
  • Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, meals or grain by-products; Animal feeds such as proteins, inorganic logistics, oils and fats, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used alone or in combination of two or more.
  • the present invention is an immune function comprising at least one selected from the Enterococcus lactis WiKim0107 strain, the culture of the strain, the concentrate of the culture, the dried product of the culture, and the extract of the culture as an active ingredient It relates to a veterinary composition for controlling and preventing or treating inflammatory bowel disease.
  • Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils.
  • the veterinary composition of the present invention may further include a filler, an anti-aggregating agent, a lubricant, a wetting agent, a spice, an emulsifying agent, a preservative, and the like.
  • the active ingredient is rapidly, sustained or It can be formulated using methods well known in the art to provide delayed release, and the formulations are powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories. , Sterile injectable solutions, sterile external preparations, and the like.
  • the veterinary composition according to the present invention may vary depending on the age, sex, and weight of the animal, and may be administered once to several times a day, and the dosage may be increased or decreased depending on the route of administration, sex, weight, age, and the like. Therefore, the dosage does not limit the scope of the present invention in any way.
  • take skate (g) purchased from the Skate Farming Corporation in Youngsanpo, Naju, Jeollanam-do, dilute it with sterilized physiological saline, spread on a solid medium for separating MRS lactic acid bacteria, and incubate for 48 hours at 30°C.
  • Different microorganisms were separated and used according to the shape of.
  • the isolated microorganisms were cultured at 30° C. for 48 hours in minimal nutrient medium (1% glucose, 0.5% yeast extract).
  • the macrophage cell line Raw264.7 cells used in the present invention was pre-sale and used from the Korean Cell Line Bank (KCLB, Seoul, Korea).
  • Cell culture medium was used by adding 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (100U/ml) to DMEM (Dulbecco's modified Eagle's medium, Gibco, Co., USA) medium, and 37°C, 5% Incubated for 48 hours in CO 2 conditions.
  • FBS fetal bovine serum
  • DMEM Dulbecco's modified Eagle's medium, Gibco, Co., USA
  • Raw264.7 cells were dispensed into a 96-well plate at a concentration of 1 ⁇ 10 5 cells/ml and incubated for 3 hours, followed by treatment with LPS (1 ⁇ g/ml) and samples, and cultured for 24 hours.
  • DMEM medium containing 10% MTS solution in the cultured 96-well plate was treated with 100 ⁇ l of each well, incubated for 3 hours, and absorbance at 490 nm using an ELISA microplate reader (Infinite 200 pro, TECAN, Austria). Was measured. Cell viability was calculated using the following formula (1).
  • DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (100U/ml) was dispensed into a 96-well plate at a concentration of 1 ⁇ 10 5 cells/ml, and the samples were treated for 1 hour.
  • LPS (1 ⁇ g / ml) was treated and incubated for 24 hours in a 37 °C, 5% CO 2 incubator.
  • Raw264.7 cells were dispensed into a 96-well plate at a concentration of 1 ⁇ 10 5 cells/ml and incubated for 2 hours, and then each sample was treated by concentration and incubated for 1 hour. . Thereafter, LPS (1 ⁇ g/ml) was treated and incubated for 24 hours in a 37°C, 5% CO 2 incubator.
  • the obtained supernatant was used as a sample, and the absorbance was measured at 450 nm using a Quantikine ELISA kit (R&D system, USA), and the measured pro-inflammatory cytokines were TNF- ⁇ , interleukin-1 ⁇ (IL- 1 ⁇ ) and interleukin-6 (IL-6) production was analyzed by the sandwich-ELISA method according to the experimental method specified in the kit.
  • the skate microorganism Enterococcus lactis WiKim0107 with excellent anti-inflammatory activity was identified through 16S ribosomal DNA gene sequence analysis. After taking the cells of the selected microorganism and washing the cells twice in sterilized physiological saline, DNA was extracted using a DNeasy tissue kit (Qiagen, Valecia, CA, USA). Universal primer for amplification of 16S ribosomal DNA gene of extracted DNA; 27F (5'-AGAGTTTGATCATGGCTCAG-3') (SEQ ID NO: 1) and 1492R (5'-GGATACCTTGTTACGACTT-3') (SEQ ID NO: 2) primers were used.
  • PCR reaction in 10 ⁇ l of Takara Perfect Premix (Takara, Japan) containing 0.4mM dNTP, 0.5 unit of Taq polymerase, and 4mM Mg 2+ , 1 ⁇ l of DNA template (20 ⁇ g/ml), 1.0 ⁇ M forward primer and 1.0 ⁇ M reverse primers were added at 1 ⁇ l each, and distilled water was added to the rest to obtain a total volume of 20 ⁇ l.
  • PCR amplification was performed with a Mastercycler gradient (Eppendorf, Hamburg, Germany). The PCR reaction was performed at 95°C for 5 minutes (initial denaturation), 94°C for 45 seconds (denaturation), 52°C for 45 seconds (annealing), 72°C for 1 minute (extension) for 30 cycles, and 72°C for 5 minutes. Final extension was performed.
  • the amplified fragment of about 1400bp was transformed after binding to a T vector (Invitrogen, Carlsbad, CA, USA). Base sequence determination was performed using a T vector sequencing primer,
  • the results were identified by comparison with the ribosomal DNA gene sequencing of GenBank (NCBI, Bethesda, MD, USA) using the BLAST analysis program (http://www.ncbi.nlm.nih.gov).
  • the determined nucleotide sequence was aligned with Clustal_W and BioEdit programs, and the generated gap was treated as a missing trait in the subsequent analysis process.
  • the calculation of the genetic distance between nucleotide sequences and the generation of neighbor-joining, maximum-likelihood and parsimony phylogenies were performed using the Mega program, and bootstrap analysis was performed with the same specifications for each of the above three analyses to determine the support of the phylogeny. (1,000 replicates).
  • Raw264.7 cells were dispensed into a 96-well culture plate under a condition of 5 ⁇ 10 3 cells/well and stabilized for 24 hours.
  • MTS assay Promega
  • the Raw264.7 cells in 96-well culture plate 5 ⁇ 10 3 cells / well seeded in condition was stabilized for 24 h, LPS (1 ⁇ g / ml) and 10 5 ⁇ 10 7 CFU / ml of Enterobacter nose kusu lactis ( Enterococcus lactis ) was treated respectively. After culturing for 24 hours, each cell culture solution was separated, and the change in NO production was analyzed using a grease reagent system (Promega).
  • Raw264.7 cells were dispensed in a 6-well culture plate under conditions of 1 ⁇ 10 5 cells/well and stabilized for 24 hours, followed by LPS (1 ⁇ g/ml) and 10 5 ⁇ 10 7 CFU/ml of Enterococcus rock Teeth ( Enterococcus lactis ) were each treated and cultured for 24 hours. Each cell was stained with CellRox Deep Red Reagent (Thermo Fisher Scientific), and then the change in ROS production was analyzed using a flow cytometer.
  • the primers for ⁇ -actin, iNOS, interleukin (IL)-1 ⁇ , IL-6, TNF- ⁇ (tumor necrosis factor alpha), and COX-2 were purchased from TaqMan Gene Expression assay (Applied Biosystems). The relative expression levels were analyzed using ABI QuantStudio 6 Flex Real Time-PCR and TaqMan PCR Master Mix. The relative expression levels of each gene were quantified with ⁇ -actin and calculated by the ⁇ Ct method.
  • a 5-week-old male mouse (C57BL/6N, Japan SLC Inc.) was purchased from the central experimental animal, adapted for one week, and used in the experiment, and the mice in a healthy state were used for the experiment by observing the general condition during the adaptation period.
  • the breeding environment was maintained at a temperature of 23 ⁇ 3°C, a humidity of 50 ⁇ 5%, and a contrast period of 12 hours (07:00-19:00/lighting time).
  • the experimental animals were reared in a polycarbonate cage (200 ⁇ 320 ⁇ 145mm, Three-shine Co., Daejon Korea) in 3 animals per group, and the feed was Harlan 2018S (Harlan TM , USA) for mice. I was fed free.
  • RO reverse osmosis
  • the experimental group was divided into a normal group (WT), a control group (Con), and an Enterococcus lactis administration group (WiKim0107), and the sample was administered orally using a mouse zone at a concentration of 10 8 CFU/100 ⁇ l. I did.
  • the sample administration period was administered daily for a total of 2 weeks, and the mice were sacrificed at 2 weeks to analyze the immune enhancing effect.
  • DMEM medium Dulbeco's modified eagle's media; Gibco
  • Fetal bovine serum Gibco
  • Each spleen tissue was extracted using DMEM medium containing 1% FBS and a 40 ⁇ m cell strainer (Falcon), and then dispensed into 5 ml FACs tubes (Falcon) under 1 ⁇ 10 6 cell conditions.
  • DSS dextran sulfate sodium salt
  • the experimental group was divided into a normal group (WT), a control group (Con), a positive control group (5-ASA), and an Enterococcus lactis administration group (WiKim0107), and the sample administration was conducted at a concentration of 10 8 CFU/100 ⁇ l. It was orally administered using a mouse bolus. The sample administration period was 3 weeks in total and was administered daily. After 2 weeks of sample administration, 5% DSS negative water was freely fed for 6 days to the experimental group excluding the normal group (WT), and mice were sacrificed at the 3rd week of sample administration. The improvement effect was analyzed.
  • DAI Disease activity index
  • DAI Disease activity index score Score Weight loss Stool consistency Visible blood in feces 0 No weight loss Normal No bleeding One 1 ⁇ 5% 2 6-10% Loose Slight bleeding 3 11-15% 4 15% or more Diarrhea Gross bleeding
  • Example 1 Selection of lactic acid bacteria with excellent anti-inflammatory activity
  • TNF- ⁇ , IL-1 ⁇ and IL-6 which are cytokines produced by Raw264.7 cells by LPS stimulation.
  • IL-1 ⁇ production was measured as 45.7 pg/ml.
  • IL-6 production was also measured as 761.1pg/ml, and showed a tendency to decrease significantly compared to the group treated with only LPS (1211.1pg/ml) (Fig. 1D).
  • the WiKim0107 strain was finally selected, and as a result of confirming the survival rate of Raw264.7 cells by MTS assay, it showed a high survival rate of 130% or more compared to the control, and the cells according to the number of viable cells Since there was no decrease in survival rate, it was confirmed that there was no significant toxic reaction to Raw264.7 cells (FIG. 2).
  • the new strain WiKim0107 isolated from skates was 97% identical to the Enterococcus lactis standard strain BT, and Enterococcus lactis WiKim0107 ( Enterococcus lactis WiKim0107 ).
  • the Enterococcus lactis WiKim0107 was deposited with the Agricultural Genetic Resource Center of the National Academy of Agricultural Sciences on March 8, 2019, and was given the deposit number KACC 81090BP.
  • Enterobacter nose kusu lactis cytotoxicity of Enterobacter nose kusu lactis (Enterococcus lactis) through the cell proliferation of RAW264.7 cells not inhibited by the treatment of (Enterococcus lactis) is no, the cell proliferation is higher than the control group and the LPS It was confirmed that there is an immunity enhancing effect through being lower than that of the treated inflammation group (FIG. 3).
  • cytokines IL-1 ⁇ , IL-6, TNF- ⁇ , COX-2
  • IL-1 ⁇ , IL-6, TNF- ⁇ , COX-2 Changes in gene expression of cytokines (IL-1 ⁇ , IL-6, TNF- ⁇ , COX-2) expressed by the activation of immune cells to confirm the immune enhancing efficacy of Enterococcus lactis Observed.
  • gene expression of cytokines was increased in the experimental group treated with Enterococcus lactis compared to the control group, and a low gene expression increased compared to the inflammatory group treated with LPS (FIG. 5).
  • Example 5 Enterococcus lactis in an animal model ( Enterococcus lactis ) Of the immune system
  • Enterococcus lactis Enterococcus lactis
  • Enterococcus lactis was orally administered to C57BL/6N mice for 2 weeks to confirm the immune enhancing efficacy of Enterococcus lactis in an animal model, and then the mice were sacrificed. During the administration period, no change in body weight and no gross signs of abnormality were observed in the mice, and it was found that there is no toxicity of Enterococcus lactis . After separating the cells from the spleen tissue, the number of immune cells (T cells, B cells, NK cells, macrophages, dendritic cells) was confirmed using a flow cytometer. As a result, Enterococcus lactis was compared with the normal group and the control group.
  • Example 6 Enterococcus lactis in an animal model ( Enterococcus lactis ) To improve inflammatory bowel disease
  • T cells T cells, B cells, NK cells, macrophages, dendritic cells
  • the number of immune cells was decreased, and it was observed that the decrease in the number of immune cells was alleviated in the experimental group administered with the positive control group and Enterococcus lactis compared to the control group (FIG. 8).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des bactéries lactiques Enterococcus lactis ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et leur utilisation. L'Enterococcus lactis n'a pas de cytotoxicité, a un effet d'amplification immunitaire et une génération de NO et des effets d'augmentation de la génération de ROS, augmente l'expression de cytokines inflammatoires et le nombre de cellules immunitaires, et a un effet d'atténuation des maladies inflammatoires chroniques intestinales dans un modèle animal de maladie intestinale inflammatoire, et par conséquent, l'Enterococcus lactis peut être très utile dans un aliment fonctionnel de santé, un produit médicinal, une composition d'aliment, ou une composition vétérinaire pour réguler des fonctions immunitaires et prévenir, soulager ou traiter les maladies inflammatoires chroniques intestinales.
PCT/KR2020/006170 2019-05-09 2020-05-11 Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation WO2020226467A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0054261 2019-05-09
KR1020190054261A KR102149185B1 (ko) 2019-05-09 2019-05-09 면역기능 조절 및 염증성 장질환의 개선효과를 갖는 엔테로코쿠스 락티스 WiKim0107 균주 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2020226467A1 true WO2020226467A1 (fr) 2020-11-12

Family

ID=72292048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/006170 WO2020226467A1 (fr) 2019-05-09 2020-05-11 Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation

Country Status (2)

Country Link
KR (1) KR102149185B1 (fr)
WO (1) WO2020226467A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039645A1 (fr) * 2021-09-20 2023-03-23 Hudson Institute of Medical Research Isolats d'enterococcus biothérapeutiques

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102486789B1 (ko) * 2019-07-19 2023-01-11 한국 한의학 연구원 엔테로코쿠스 락티스를 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130046896A (ko) * 2011-10-28 2013-05-08 대상에프앤에프 주식회사 대사질환 또는 염증질환 치료 및 예방 효과가 있는 락토바실러스 플란타륨 ｄｓｒ920 및 이의 용도
KR20160061611A (ko) * 2014-11-24 2016-06-01 고려대학교 산학협력단 신규한 엔테로코커스 페시움 l11 균주 및 이를 유효성분으로 포함하는 생균제 조성물
KR20170049216A (ko) * 2015-10-28 2017-05-10 고려대학교 산학협력단 신규한 락토바실러스 가세리 균주 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) * 1991-04-08 1991-05-22 Unilever Plc Probiotic
KR101327295B1 (ko) * 2011-12-16 2013-11-11 한국식품연구원 신규한 면역기능 증진 활성이 있는 엔테로코커스 속 균주 및 이의 용도
KR101677187B1 (ko) * 2016-06-28 2016-11-17 바이오제닉스코리아 주식회사 면역증진 및 장내환경개선용 건강기능성 음료
KR20190111584A (ko) * 2018-03-23 2019-10-02 (주)바이오일레븐 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 퍼멘툼 균주
KR20190111582A (ko) * 2018-03-23 2019-10-02 (주)바이오일레븐 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130046896A (ko) * 2011-10-28 2013-05-08 대상에프앤에프 주식회사 대사질환 또는 염증질환 치료 및 예방 효과가 있는 락토바실러스 플란타륨 ｄｓｒ920 및 이의 용도
KR20160061611A (ko) * 2014-11-24 2016-06-01 고려대학교 산학협력단 신규한 엔테로코커스 페시움 l11 균주 및 이를 유효성분으로 포함하는 생균제 조성물
KR20170049216A (ko) * 2015-10-28 2017-05-10 고려대학교 산학협력단 신규한 락토바실러스 가세리 균주 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENYACOUB, J . ET AL.: "Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in Mice", THE JOURNAL OF NUTRITION, vol. 135, no. 5, 2005, pages 1171 - 1176, XP002415804 *
MARKS, S. L.: "How I treat inflammatory bowel disease in dogs", WORLD SMALL ANIMAL VETERINARY ASSOCIATION WORLD CONGRESS PROCEEDINGS, 24 July 2009 (2009-07-24), Retrieved from the Internet <URL:https://www.vin.com/apputil/content/defaultadv1.aspx?pId=11290&catId=33328&id=4252728> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039645A1 (fr) * 2021-09-20 2023-03-23 Hudson Institute of Medical Research Isolats d'enterococcus biothérapeutiques

Also Published As

Publication number Publication date
KR102149185B1 (ko) 2020-08-28

Similar Documents

Publication Publication Date Title
KR102128287B1 (ko) 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
US10918678B2 (en) Faecalibacterium prausnitzii strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation
KR102128289B1 (ko) 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l&#39;obésité, et utilisation correspondante
KR102151666B1 (ko) 신규 유산균 및 이의 용도
WO2021137602A1 (fr) Souche de lactobacillus fermentum, et composition pour la prévention ou le traitement de maladies métaboliques, comprenant celle-ci
WO2020226467A1 (fr) Souche d&#39;enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d&#39;atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2020226468A1 (fr) Souche de pediococcus inopinatus ｗikim0108 ayant un effet de régulation de la fonction immunitaire et de soulagement d&#39;une maladie intestinale inflammatoire et son utilisation
WO2018043864A1 (fr) Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d&#39;améliorer la fonction sexuelle, et composition la comprenant
WO2023140657A1 (fr) Analyse de la flore intestinale chez des patients greffés du foie, surveillance ainsi de l&#39;état de transplantation, et composition de théranostic immunomodulatrice
WO2020091180A9 (fr) Composition pour prévenir ou traiter l&#39;ostéoporose secondaire comprenant des probiotiques en tant que principe actif
WO2021015514A1 (fr) Composition comprenant enterococcus lactis en tant que principe actif pour la prévention, le soulagement, ou le traitement de la stéatose hépatique
WO2021125822A1 (fr) Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif
WO2017191856A1 (fr) Effet antidiabétique du gypénoside 75
WO2020226469A1 (fr) Composition pour la réduction des rides de la peau et l&#39;hydratation de la peau, comprenant enterococcus lactis en tant que composant efficace
WO2020071660A1 (fr) Composition anti-âge contenant comme principe actif une souche d&#39;akkermansia muciniphila ou une culture de cette dernière
JP7342192B1 (ja) 化学療法による腸管損傷の関連病変又は細菌叢の不均衡の予防或いは補助療法におけるバチルスコアグランスｂｃ１９８又はその代謝産物の用途
WO2021261929A1 (fr) Nouvelle souche de lactobacillus reuteri et utilisation associée
WO2021015515A1 (fr) Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif
KR102506366B1 (ko) 락토바실러스 플란타럼 ku15120 균주 또는 이의 용도
WO2023229263A1 (fr) Composition pour prévenir, traiter ou atténuer des maladies métaboliques comprenant une souche de lactobacillus plantarum nchbl-004 ou un milieu de culture de celle-ci
WO2024063543A1 (fr) Composition pour la prévention ou le traitement du cancer à l&#39;aide d&#39;une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes
WO2022250192A1 (fr) Nouvelle souche lactobacillus fermentum dérivée du kimchi ayant une excellente activité anti-inflammatoire et composition pour la prévention ou le traitement des maladies inflammatoires la comprenant
WO2023121331A1 (fr) Composition destinée à la prévention, à l&#39;amélioration ou au traitement d&#39;une maladie respiratoire contenant un extrait de lysimachia mauritiana en tant que principe actif
KR102485269B1 (ko) 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20801843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20801843

Country of ref document: EP

Kind code of ref document: A1